ProtoKinetix Inc (PKTX)

[Past and present]

(PKTX) PR NEWS...ProtoKinetix Signs Collaborative Agreement with Multi-National Corporation
VANCOUVER, British Columbia, November 17, 2008 /PRNewswire-FirstCall/ -- ProtoKinetix, Inc. , a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that it has entered into a collaborative research agreement with a global multi-billion dollar company that provides products and services to pharmaceutical and biotechnology companies, as well as academic and research institutions. This company is recognized worldwide as one of the leading innovators of cell and tissue engineering. Due to the extreme sensitivity and highly competitive nature of this industry, the company has requested that, at this time, their name be kept confidential.
ProtoKinetix has a patented family of molecules (AAGP(TM)) that have clearly demonstrated a superior ability to protect cells and tissues subjected to hostile conditions. This collaboration will provide a platform to develop cell preservation formulations for specific applications of AAGP(TM) in a wide range of cell and tissue therapies.

Cell therapy is one of the fastest growing approaches to the treatment of disease. The survival of cells is an essential component for the success of these therapies.